700 patients110,866 observations180 daysLIVE
← Patients

Patient P-02328

Synthetic patientMETA-24 · Day 175 · 55–64 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 started — Baseline state S14
  2. Day 68 SC-12 recommended — Supportive Compound SC-12
  3. Day 69 Patient accepted — Started SC-12 in the companion
  4. Day 74 GI-04 recommended — GI Support Protocol GI-04
  5. Day 75 Patient accepted — Started GI-04 in the companion
  6. Day 75 GI symptom burden −13% vs expected — Supportive Compound SC-12
  7. Day 81 Tolerance state changed — Unstable → Improving
  8. Day 83 GI symptom burden −26% vs expected — GI Support Protocol GI-04
  9. Day 89 Tolerance state changed — Unstable → Improving
  10. Day 93 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  11. Day 93 ME-01 recommended — Monitoring Escalation ME-01
  12. Day 94 Patient accepted — Started ME-01 in the companion
  13. Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 93.

Primary contributors, last 14 days
  • GI instability+7
  • Treatment adherence-4
  • Nutritional resilience+2

What helped?

  • Supportive Compound SC-12Day 68
    Result: symptom burden −13%
  • GI Support Protocol GI-04Day 74
    Result: symptom burden −26%
  • Monitoring Escalation ME-01Day 93
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
57%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 64% showed improvement
  • median effect visible after 10 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
12 min
improving · +4.6 vs previous 14 d
Sleep duration
Wearable
6.9 h
stable · -0.1 vs previous 14 d
Energy level
Daily log
4.3/10
stable · -0.1 vs previous 14 d
Steps
Wearable
1,052
improving · +310 vs previous 14 d
GI burden
Companion
49.4/100
improving · -7.2 vs previous 14 d
Adherence
Companion
44.6 %
worsening · -3.6 vs previous 14 d
Sleep quality
Wearable
36.9/100
stable · +1.6 vs previous 14 d
Glucose, CGM daily mean
CGM
141 mg/dL
stable · -1.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 33 from the failing basin, 54 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    59% improved among 32 similar · onset 10 d · confidence 70%
  • CR-01 Clinician Review
    100% improved among 6 similar · onset 5 d · confidence 70%
  • DT-01 Dosing / Timing Recommendation
    60% improved among 5 similar · onset 5 d · confidence 70%
  • More protein
    GI -5.3 next day on high-intake days · n 18
Would not help
  • Keep ultra-processed low
    GI +5.2 next day on high-intake days · n 22
  • Keep caffeine low
    GI +4.7 next day on high-intake days · n 23
  • Keep simple carbs low
    GI +4.4 next day on high-intake days · n 25
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -5.3supporter · 95%
  • Ultra-processed food
    +5.2detractor · 95%
  • Caffeine
    +4.7detractor · 95%
  • Simple carbohydrates
    +4.4detractor · 95%
  • Dietary fat load
    +3.4detractor · 73%
  • Insoluble fibre
    +2.7detractor · 68%
  • Alcohol
    +1.2no signal · 26%
  • Histamine load
    +0.8no signal · 18%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓50
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 49 and rising
  • Inflammatory signalling ↓50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 48
  • Autonomic recovery ↓45
    • WearableResting HR 74 bpm
    • Wearable1,052 steps/day
  • Drug metabolism and exposure ↑40
    • DNACYP2D6 poor metabolizer → higher exposure
  • Butyrate / short-chain fatty acid production ↓20
    • Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 46/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
47 ms
Sleep
6.8 h
Steps
1,714
Resting HR
74 bpm
Daily log: GI score 49, nutritional resilience 49, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0211523%S14GI-04improved75
P-0265927%S09——69
P-0235623%S08——69
P-0259129%S13——68
P-0226528%S07GI-04no change67
P-0253029%S07——67
P-0243623%S05——67
P-0236731%S03——67
P-0230927%S09——67
P-0233428%S04GI-04improved66
P-0210924%S04——66
P-0223330%S16CR-01improved66